beigene china | BeiGene

Keyword	CPC	PCC	Volume	Score	Length of keyword
beigene china	0.68	0.3	7861	66	13
beigene	0.94	0.3	838	96	7
china	0.02	0.6	8590	80	5

Keyword	CPC	PCC	Volume	Score
beigene china	1.56	0.4	8920	69
beigene chinese	1.61	0.2	4984	71

Search Results related to beigene china on Search Engine

BeiGene - Wikipedia
wikipedia.org

https://en.m.wikipedia.org/wiki/BeiGene

WebBeiGene also acquired Celgene's operations in China as well as the rights to commercialize Abraxane, Revlimid and Vidaza, Celgene's approved drugs in China. As part of the deal, Celgene made a $150 million equity investment in BeiGene and acquired the rights for the sale of tislelizumab overseas for $263 million, with another $980 million plus ...

DA: 25 PA: 32 MOZ Rank: 71

BeiGene | Cancer Has No Borders. Neither Do We.
beigene.com

https://www.beigene.com/

WebMar 14, 2024 · BeiGene is a global, science-driven oncology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide.

DA: 72 PA: 26 MOZ Rank: 77

百济神州 | 百创新药，济世惠民
beigene.com.cn

https://www.beigene.com.cn/

Web2024年02月26日. 百济神州是一家全球性生物科技公司，专注于开发和商业化创新、可负担的抗肿瘤药物，旨在为全球患者改善治疗效果、提高药物可及性。通过强大的自主研发能力与外部战略合作，我们不断加速开发多元、创新的药物管线，打造广泛的候选药物和产品组合。我们致力于为全球更多患者全面改善药物可及性。百济神州在全球五大洲打造了一支超过8,500人的团队，并在中国北京、美国麻省剑桥和瑞士巴塞尔设立了主要办事处。

DA: 64 PA: 34 MOZ Rank: 40

BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
beigene.com

https://ir.beigene.com/news/beigene-receives-10th-approval-for-pd-1-inhibitor-tislelizumab-in-china/a92a3ed5-ae46-440e-90d2-8024a2c13930/

WebFeb 24, 2023 · BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China. Feb 24, 2023 7:00 AM. NMPA grants approval for first-line use in combination with chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression. BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. -- (BUSINESS WIRE)-- BeiGene (NASDAQ ...

DA: 96 PA: 66 MOZ Rank: 91

BeiGene Expands Collaboration with Novartis to Develop and
beigene.com

https://ir.beigene.com/news/beigene-expands-collaboration-with-novartis-to-develop-and-commercialize-beigene-s-tigit-inhibitor-and-market-five/90967044-2f65-4774-942e-7edbdc880f12/

WebDec 20, 2021 6:15 AM. Strategic collaboration expected to advance clinical development of ociperlimab in combination with tislelizumab, including initiation and funding by Novartis of additional studies. BeiGene expands commercial portfolio in China broad markets with marketing rights for five Novartis Oncology products.

DA: 99 PA: 36 MOZ Rank: 95

BeiGene Announces the Approval in China of BLINCYTO
businesswire.com

https://www.businesswire.com/news/home/20201207005670/en/BeiGene-Announces-the-Approval-in-China-of-BLINCYTO%C2%AE-Blinatumomab-for-Injection-for-Adult-Patients-with-Relapsed-or-Refractory-B-Cell-Precursor-Acute-Lymphoblastic-Leukemia-ALL

WebDec 8, 2020 · Developed by Amgen and licensed to BeiGene in China under a strategic collaboration commenced earlier this year, this is the first approval for BLINCYTO in China and BeiGene’s first...

DA: 81 PA: 4 MOZ Rank: 33

A rising oncology powerhouse in China, BeiGene looks to …
pharmavoice.com

https://www.pharmavoice.com/news/beigene-china-cancer-Christiane-Langer/644900/

WebMar 14, 2023 · A rising oncology powerhouse in China, BeiGene looks to strengthen its international punch. To expand its reach, Christiane Langer, the company’s head of medical affairs, is leaning on connections and singularity over fitting in a box. Published March 14, 2023. Michael Gibney Senior Editor & Writer. Christiane Langer …

DA: 42 PA: 62 MOZ Rank: 82

BeiGene Announces First Commercial Manufacturing Approval …
beigene.com

https://ir.beigene.com/news/beigene-announces-first-commercial-manufacturing-approval-for-its-state-of-the-art-biologics-facility-in-guangzhou-china/6fc422dd-2bb7-4df0-963d-58ac36694e18/

WebApr 7, 2021 · BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China. Apr 07, 2021 7:00 PM. Commercial supply of tislelizumab for China now expanded with wholly owned manufacturing site.

DA: 57 PA: 22 MOZ Rank: 9

BeiGene Announces the Approval of XGEVA® (Denosumab) in China …
businesswire.com

https://www.businesswire.com/news/home/20201119006271/en/BeiGene-Announces-the-Approval-of-XGEVA%C2%AE-Denosumab-in-China-for-the-Prevention-of-Skeletal-Related-Events-in-Patients-With-Bone-Metastases-From-Solid-Tumors-and-in-Patients-With-Multiple-Myeloma

WebNov 20, 2020 · Developed by Amgen and licensed to BeiGene in China under a strategic collaboration commenced earlier this year, XGEVA is also approved and marketed in China for the treatment of adults and...

DA: 56 PA: 19 MOZ Rank: 82

BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 …
businesswire.com

https://www.businesswire.com/news/home/20211214006363/en/BeiGene-Announces-Closing-of-Its-RMB22.2-Billion-US3.5-Billion-Initial-Public-Offering-on-the-STAR-Market-of-the-Shanghai-Stock-Exchange-in-China

WebDec 15, 2021 · BeiGene has granted China International Capital Corporation Limited a 30-day overallotment option for up to 17,258,000 additional RMB Shares.

DA: 18 PA: 79 MOZ Rank: 89